1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

AdvaMed CEO Says Some Top Agenda Items For the Year Are ‘Taking A Back Seat’ To Address COVID-19

AdvaMed has had to adjust to the new COVID-19 reality like everyone else. In an exclusive interview with Medtech Insight, the head of the industry group says they are putting some key issues such as user-fee negotiations, anti-kickback legislation and breakthrough technologies reform on the back burner to prioritize dealing with the current crisis.

comments made by Scott Whitaker (left) and Kevin Lobo (right)
ADVAMED CEO SCOTT WHITAKER (LEFT) AND CHAIRMAN KEVIN LOBO AT A September 2019 PRESS CONFERENCE • Source: Ferdous Al-Faruque

The head of the biggest medical device lobby group says the organization has had to shift its focus to prioritize the ongoing COVID-19 pandemic. Some issues that have had to take a back seat as industry addresses the current crisis include the upcoming user-fee negotiations, anti-kickback legislation and breakthrough technologies reform.

Scott Whitaker, president and CEO of AdvaMed, told Medtech Insight on 14 April that while his organization has had to shift the way it operates, it’s still working to represent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

EU Finalizes Framework For Joint Clinical Assessments Of High-Risk Devices

 
• By Amanda Maxwell

Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.

UK Take Care! Regulatory And Market Access Reforms Must Not Shut Out Medtech Growth

 
• By Ashley Yeo

Speakers at a recent UK medtech outlook conference voiced optimism about the sector’s prospects, but warned that cost burdens, over-regulation and lengthy processes will impede the capacity of local SMEs to innovate. Only 10% of NHS procured medtech comes from UK manufacturers.

Zika Virus Test Among 4 New FDA Device Classifications

 
• By Elizabeth Orr

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

Industry Execs Talk Tariff Turbulence During MD&M East

 
• By Brian Bossetta

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

More from Policy & Regulation

Zika Virus Test Among 4 New FDA Device Classifications

 
• By Elizabeth Orr

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

FDA Draft Guidance Introduces Electric Submission For Q-Sub Process

 
• By Brian Bossetta

The US FDA says its updated draft guidance represents one of several steps the agency is taking to develop electronic submission templates for the medical device industry. The document introduces stakeholders to currently available resources for supporting their pre-subs to the agency.

Industry Execs Talk Tariff Turbulence During MD&M East

 
• By Brian Bossetta

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.